School of Medicine, Nankai University, Tianjin, China.
Department of Ultrasound, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Clin Endocrinol (Oxf). 2021 Apr;94(4):684-691. doi: 10.1111/cen.14361. Epub 2020 Dec 9.
Ultrasonography-guided radiofrequency ablation (RFA) has been used to treat low-risk small papillary thyroid carcinoma (PTC) and yielded promising results. However, little research has been conducted on the application of RFA for the management of T1bN0M0 PTC. Therefore, this study was to compare the midterm outcome of RFA with that of surgery for the treatment of clinical solitary T1bN0M0 PTC.
This is a retrospective study.
In total, 182 patients with solitary T1bN0M0 PTC between April 2014 and May 2019 were treated with RFA or surgery (n = 91/group).
The primary end points were local tumour progression and complication rates. Local tumour progression were defined as: (a) new or persistent PTC confirmed by core needle biopsy; (b) cervical lymph node metastasis (LNM) confirmed by core needle biopsy or surgery; (c) ablation zone increased in the RFA group.
In the RFA group, local tumour progression was seen in four patients (4.4%, three persistent PTC and one LNM). In the surgery group, two patients (2.2%) developed LNM; no new or persistent PTC was confirmed. There was no significant difference between the two groups in local tumour progression. Permanent hypoparathyroidism was observed in four patients (4.4%) in the surgery group, while no major or minor complications were observed in the RFA group.
Ultrasonography-guided RFA is feasible and safe for treating solitary T1bN0M0 PTC, so it may be considered an alternative to surgery in select patients, especially those who are ineligible for or refusal of surgery.
超声引导下射频消融(RFA)已被用于治疗低危小型甲状腺乳头状癌(PTC),并取得了良好的效果。然而,对于 T1bN0M0 期 PTC 的 RFA 管理应用,研究甚少。因此,本研究旨在比较 RFA 与手术治疗临床单发 T1bN0M0 期 PTC 的中期结果。
这是一项回顾性研究。
2014 年 4 月至 2019 年 5 月,共 182 例单发 T1bN0M0 期 PTC 患者接受 RFA 或手术治疗(每组 n=91)。
主要终点为局部肿瘤进展和并发症发生率。局部肿瘤进展定义为:(a)经核心针活检证实的新的或持续性 PTC;(b)经核心针活检或手术证实的颈部淋巴结转移(LNM);(c)RFA 组消融区增大。
RFA 组有 4 例(4.4%)出现局部肿瘤进展,包括 3 例持续性 PTC 和 1 例 LNM。手术组有 2 例(2.2%)发生 LNM,无新的或持续性 PTC 被证实。两组间局部肿瘤进展无显著差异。手术组有 4 例(4.4%)发生永久性甲状旁腺功能减退,而 RFA 组无重大或轻微并发症。
超声引导下 RFA 治疗单发 T1bN0M0 期 PTC 是可行且安全的,因此对于某些患者,特别是那些不适合手术或拒绝手术的患者,可能是一种替代手术的方法。